Lupin announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after
closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the U.S. FDA between 13 January 2020 and 17 January 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
